US Stock Insider Trading | Solid Biosciences disclosed 7 insider transactions on February 6

2026-03-07 02:50:41

On February 6, 2026, Solid Biosciences (SLDB) disclosed seven insider trading transactions. Director Cumbo Alexander sold 48,900 shares on February 4, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 6, 2026	Executive	Howton David T	February 4, 2026	Sell	18,900	6.44	121,700
February 6, 2026	Director	Cumbo Alexander	February 4, 2026	Sell	48,900	6.44	315,100
February 6, 2026	Executive	Tan Kevin	February 4, 2026	Sell	14,800	6.44	95,200
February 6, 2026	Executive	Brooks Gabriel	February 4, 2026	Sell	12,600	6.44	81,300
February 6, 2026	Executive	Hanrahan Jessie	February 4, 2026	Sell	12,300	6.44	79,500
February 6, 2026	Executive	Herzich Paul	February 4, 2026	Sell	10,900	6.44	70,200
February 6, 2026	Director	Ganot Ilan	February 4, 2026	Sell	7,205	6.44	46,400
February 2, 2026	Executive	Hanrahan Jessie	February 2, 2026	Sell	26,500	6.44	170,800
February 2, 2026	Executive	Howton David T	February 2, 2026	Sell	37,800	6.44	243,100
February 2, 2026	Executive	Herzich Paul	February 2, 2026	Sell	26,300	6.44	169,000

【Company Profile】

Solid Biosciences Inc., formerly known as SOLID Ventures Management, LLC, was established in March 2013 as a Delaware limited liability company. The company is a life sciences firm focused on advancing current and future gene therapy candidate drugs, collectively referred to as candidates, including SGT-003 for Duchenne muscular dystrophy, or DMD, SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), and additional assets for treating cardiac and other diseases at various stages of development with different investment levels. The company is developing a diversified pipeline targeting rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-centered and founded by individuals directly affected by Duchenne, the company’s mission is to improve the daily lives of patients suffering from these devastating diseases.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes